Clinical Trial: Behavioral Intervention Trial for HIV-Infected Injection Drug Users

This study is no longer recruiting patients.

Sponsors and Collaborators: Centers for Disease Control and Prevention
Health Services Resource Adminstration - HIV/AIDS Bureau
Information provided by: Centers for Disease Control and Prevention
ClinicalTrials.gov Identifier: NCT00146445

Purpose

The purpose of this study is to test whether a ten-session behavioral intervention for HIV-infected injection drug users is effective in reducing sex and injection risk behaviors that put others at risk for HIV infection, increasing access to or utilization of HIV primary health care, and increasing adherence to HIV medications.
Condition Intervention Phase
Peer Mentoring Intervention
Video & Discussion Intervention (comparison condition)
 Behavior: Peer Mentoring Intervention
Phase II
Phase III

MedlinePlus consumer health information 

Study Type: Interventional
Study Design: Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study

Official Title: Intervention for Seropositive Injection Drug Users - Research and Evaluation (INSPIRE)

Further Study Details: 
Primary Outcomes: - unprotected vaginal/anal sex with HIV-negative or unknown serostatus partners in the past 3 months; - lending needle or sharing cotton, cooker, or rinse water with HIV-negative or unknown serostatus partners in the past 3 months; -health care visits for HIV primary care in the past 6 months; -90% or more adherence to HIV medication yesterday and in the past week
Secondary Outcomes: -Proportion of HIV status disclosure to sex partners
Expected Total Enrollment:  1000

Study start: August 2001;  Study completion: June 2007
Last follow-up: March 2005;  Data entry closure: April 2005

INSPIRE is a four-site (Baltimore, Miami, New York and San Francisco) randomized control trial to develop and evaluate the efficacy of a ten-session intervention for HIV-positive injection drug users. The primary goals of the intervention are to:

  1. decrease sex and injection risk behaviors that put others at risk for HIV infection,
  2. increase access to or utilization of HIV primary health care, and
  3. increase adherence to HIV medications.

The intervention arm consists of 7 group sessions, 2 individual sessions, and one community experience. The control arm consists of 8 group sessions, aiming at controlling for demand (1st session) and attention (8 group sessions). Behavioral assessments and blood draws (for viral load and CD4 testing) occur at baseline, 6, and 12 month follow-up; a 3 month assessment involves behavioral assessment only. 1161 participants took baseline. Of these, 966 were randomized into the study, and 840, 807, and 821 participants took 3, 6, and 12 month follow-up assessments, respectively.

Eligibility

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both
Criteria

Inclusion Criteria:

  • 18 years of age or older
  • self-identify as a person who has injected drugs in the last 12 months
  • self-identify as a person who has had sex with at least one opposite sex partner within the last 3 months
  • self-identify as HIV-seropositive
  • be confirmed as HIV seropositive through oral fluid (saliva) HIV testing
  • live in the geographic region under study,
  • agree to have their blood drawn for CD4 count and viral load testing
  • be willing to provide basic contact information (for follow-up)
  • be able to communicate in English
  • not have participated in the full-pilot of this intervention and not have enrolled previously in the present study.

Exclusion Criteria:

-

Location Information


California
      University of California - San Francisco, San Fransisco,  California,  94105,  United States

Florida
      University of Miami, Miami,  Florida,  33136,  United States

Maryland
      Johns Hopkins University, Baltimore,  Maryland,  21231,  United States

New York
      New York Academy of Medicine, New York,  New York,  10029,  United States

      Montefiore Medical Center, Bronx,  New York,  10467,  United States

Study chairs or principal investigators

David W Purcell, JD, PhD,  Principal Investigator,  Centers for Disease Control and Prevention   

More Information

Publications

Purcell DW, Metsch LR, Latka M, Santibanez S, Gomez CA, Eldred L, Latkin CA; for the INSPIRE Study Group. Interventions for Seropositive Injectors-Research and Evaluation: An Integrated Behavioral Intervention With HIV-Positive Injection Drug Users to Address Medical Care, Adherence, and Risk Reduction. J Acquir Immune Defic Syndr. 2004 Oct 1;37:S110-S118.

Study ID Numbers:  CDC-NCHSTP-2864; U22/CCU217990; U22/CCU317999; U22/CCU417998; U22/CCU918003
Last Updated:  September 6, 2005
Record first received:  September 2, 2005
ClinicalTrials.gov Identifier:  NCT00146445
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-09-13

Resources




Common Treatments

[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]

Follow Us